医学
射血分数
背景(考古学)
糖尿病
心力衰竭
内科学
安慰剂
心脏病学
2型糖尿病
随机对照试验
内分泌学
生物
病理
古生物学
替代医学
作者
Stelina Alkagiet,Κωνσταντίνος Τζιόμαλος
出处
期刊:World Journal of Diabetes
[Baishideng Publishing Group Co (World Journal of Diabetes)]
日期:2020-05-15
被引量:1
标识
DOI:10.4239/wjd.v11.i5.150
摘要
Heart failure (HF) is a major complication of diabetes mellitus (DM). Patients with DM have considerably higher risk for HF than non-diabetic subjects and HF is also more severe in the former. Given the rising prevalence of DM, the management of HF in diabetic patients has become the focus of increased attention. In this context, the findings of several randomized, placebo-controlled trials that evaluated the effects of sodium-glucose co-transporter-2 inhibitors on the risk of hospitalization for HF in patients with type 2 DM represent a paradigm shift in the management of HF. These agents consistently reduced the risk of hospitalization for HF both in patients with and in those without HF. These benefits appear to be partly independent from glucose-lowering and have also been reported in patients without DM. However, there are more limited data regarding the benefit of sodium-glucose co-transporter-2 inhibitors in patients with HF and preserved left ventricular ejection fraction, which is the commonest type of HF in diabetic patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI